https://scholars.lib.ntu.edu.tw/handle/123456789/473794
標題: | Programmed cell death-ligand 1 expression in surgically resected stage i pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes | 作者: | CHING-YAO YANG MONG-WEI LIN YIH-LEONG CHANG CHEN-TU WU PAN-CHYR YANG |
公開日期: | 2014 | 出版社: | Elsevier Ltd | 卷: | 50 | 期: | 7 | 起(迄)頁: | 1361-1369 | 來源出版物: | European Journal of Cancer | 摘要: | Background Programmed cell death-ligand 1 (PD-L1) is expressed in a group of cancers that may be suitable targets for specific immunotherapy. This study investigated the expression of PD-L1 in surgically resected stage I adenocarcinomas and correlated this with known major driver mutations and clinical outcomes. Materials and methods One hundred and sixty-three patients with surgically resected stage I adenocarcinomas were explored. Paraffin-embedded tumour sections were stained with PD-L1 antibody. Tumours with moderate-to-strong membrane staining in ?5% of tumour cells were scored as positive for PD-L1 overexpression. The driver mutation epidermal growth factor receptor (EGFR), Kirsten rat sarcoma viral oncogene homolog (KRAS), and v-raf murine sarcoma viral oncogene homolog B (BRAF) were examined by direct sequencing and anaplastic lymphoma kinsase (ALK) by immunohistochemistry. The correlations of PD-L1 expression with major driver mutations and clinicopathologic parameters were analysed. Results The overall frequency of PD-L1 overexpression was 39.9% (65/163). PD-L1 had higher positive results in tumours with higher grade differentiation and vascular invasion and PD-L1 expression was not associated with the expressions of EGFR, KRAS, BRAF and ALK. Multivariate analysis revealed that abnormal carcinoembryonic antigen (CEA) and higher grade of differentiation were risk factors for poor relapse-free survival (RFS) and PD-L1 expression correlated with better RFS. Advanced pathologic stage was the independent risk for poor overall survival (OS). Conclusions The PD-L1 expression can be used as a prognostic indicator predictive of RFS in patients with surgically resected stage I lung adenocarcinomas. There may be a possibility for immunotherapy targeting the PD-L1 pathway in patients with lung adenocarcinoma in the future. ? 2014 Elsevier Ltd. All rights reserved. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84897404380&doi=10.1016%2fj.ejca.2014.01.018&partnerID=40&md5=be7aaac02ae7bc59be43936374a82054 https://scholars.lib.ntu.edu.tw/handle/123456789/473794 |
ISSN: | 0959-8049 | DOI: | 10.1016/j.ejca.2014.01.018 | SDG/關鍵字: | anaplastic lymphoma kinase; B Raf kinase; carcinoembryonic antigen; epidermal growth factor receptor; programmed death 1 ligand 1; adult; aged; apoptosis; article; Asian; cancer grading; cancer staging; cancer surgery; controlled study; female; gene expression; gene mutation; gene sequence; human; human tissue; immunohistochemistry; lung adenocarcinoma; major clinical study; male; middle aged; oncogene K ras; outcome assessment; overall survival; priority journal; recurrence free survival; risk factor; tumor cell; tumor differentiation; tumor invasion; very elderly; young adult; Adenocarcinoma; Immunotherapy; Non-small cell lung cancer; PD-L1; Programmed cell death-ligand 1; Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antigens, CD274; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; Receptor, Epidermal Growth Factor; Survival Analysis |
顯示於: | 病理學科所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。